| HOME >> BIOLOGY >> TECHNOLOGY |
Accumulated other comprehensive income 14,058 7,835
Total shareholders' equity 294,755 251,398
Total liabilities and shareholders' equity 408,292 343,775
Note 1: Amounts were based on the preliminary purchase price
allocation from management's best estimation. They are subject to
final valuation from a third-party professional appraisal firm.
They may be significantly different from our estimate and subject
to potential adjustments. At the same time, final valuation may
also lead to potential adjustments for other accounts related to
the acquisition.
Note 2: Eight (8) ordinary shares are equal to one (1) ADS
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands of US dollars, except ADS and per ADS data)
Three Months Ended March 31,
2008 2007
Net revenues:
Laboratory services 38,443 21,676
Manufacturing services 18,617 12,143
Total net revenues 57,060 33,819
Cost of revenues:
Laboratory services (19,523) (10,881)
Manufacturing services (13,270) (7,266)
Total cost of revenues (32,793) (18,147)
Gross Profit 24,267 15,672
Operating expenses:
Selling and marketing expenses (1,407) (738)
General and administrative expenses (11,198) (9,090)
Total
'/>"/>
| SOURCE WuXi PharmaTech Copyright©2008 PR Newswire. All rights reserved |